Johnson & Johnson announced that the US FDA approved RYBREVANT FASPRO™ as the first and only dual-targeted therapy for advanced head and neck cancer.

Zhitongcaijing · 2d ago
Johnson & Johnson announced that the US FDA approved RYBREVANT FASPRO™ as the first and only dual-targeted therapy for advanced head and neck cancer.